nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—pancreatic cancer—liver cancer	0.144	0.378	CtDrD
Erlotinib—ABL1—liver cancer	0.13	0.649	CbGaD
Erlotinib—kidney cancer—liver cancer	0.121	0.317	CtDrD
Erlotinib—lung cancer—liver cancer	0.117	0.305	CtDrD
Erlotinib—MKNK1—Sorafenib—liver cancer	0.0503	0.159	CbGbCtD
Erlotinib—AURKC—Sorafenib—liver cancer	0.0503	0.159	CbGbCtD
Erlotinib—CYP1A1—liver cancer	0.0454	0.226	CbGaD
Erlotinib—FLT3—Sorafenib—liver cancer	0.0364	0.115	CbGbCtD
Erlotinib—HIPK4—Sorafenib—liver cancer	0.0321	0.101	CbGbCtD
Erlotinib—EPHA6—Sorafenib—liver cancer	0.0321	0.101	CbGbCtD
Erlotinib—STK10—Sorafenib—liver cancer	0.0289	0.0911	CbGbCtD
Erlotinib—MAP2K5—Sorafenib—liver cancer	0.0263	0.0829	CbGbCtD
Erlotinib—ALB—liver cancer	0.0253	0.126	CbGaD
Erlotinib—MAP3K19—Sorafenib—liver cancer	0.0242	0.0762	CbGbCtD
Erlotinib—UGT1A1—Sorafenib—liver cancer	0.00867	0.0273	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—liver cancer	0.00609	0.0192	CbGbCtD
Erlotinib—ABCG2—Sorafenib—liver cancer	0.00477	0.015	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—liver cancer	0.00289	0.00912	CbGbCtD
Erlotinib—CYP3A5—Sorafenib—liver cancer	0.00264	0.00833	CbGbCtD
Erlotinib—CYP2C8—Sorafenib—liver cancer	0.00254	0.00801	CbGbCtD
Erlotinib—CYP1A2—Sorafenib—liver cancer	0.00197	0.0062	CbGbCtD
Erlotinib—ABCB1—Sorafenib—liver cancer	0.00172	0.00542	CbGbCtD
Erlotinib—CYP2D6—Sorafenib—liver cancer	0.00162	0.00511	CbGbCtD
Erlotinib—ORM1—bile—liver cancer	0.00112	0.234	CbGeAlD
Erlotinib—ABCB1—Doxorubicin—liver cancer	0.00104	0.00329	CbGbCtD
Erlotinib—CYP3A4—Sorafenib—liver cancer	0.00103	0.00325	CbGbCtD
Erlotinib—CYP2D6—Doxorubicin—liver cancer	0.000983	0.0031	CbGbCtD
Erlotinib—CYP3A4—Doxorubicin—liver cancer	0.000625	0.00197	CbGbCtD
Erlotinib—Vandetanib—ABL1—liver cancer	0.000487	0.305	CrCbGaD
Erlotinib—Vandetanib—KDR—liver cancer	0.000414	0.259	CrCbGaD
Erlotinib—Vandetanib—VEGFA—liver cancer	0.000351	0.22	CrCbGaD
Erlotinib—ORM1—gall bladder—liver cancer	0.00031	0.065	CbGeAlD
Erlotinib—NR1I2—liver—liver cancer	0.000297	0.0624	CbGeAlD
Erlotinib—ALB—gall bladder—liver cancer	0.000272	0.057	CbGeAlD
Erlotinib—TNK1—liver—liver cancer	0.000218	0.0458	CbGeAlD
Erlotinib—ABL1—Idarubicin—Epirubicin—liver cancer	0.000212	0.173	CbGdCrCtD
Erlotinib—ABL1—Doxorubicin—Epirubicin—liver cancer	0.000212	0.173	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Epirubicin—liver cancer	0.000212	0.173	CbGdCrCtD
Erlotinib—Infestation—Sorafenib—liver cancer	0.000202	0.00544	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.0002	0.0054	CcSEcCtD
Erlotinib—Acute coronary syndrome—Sorafenib—liver cancer	0.000199	0.00537	CcSEcCtD
Erlotinib—Renal failure—Sorafenib—liver cancer	0.000199	0.00535	CcSEcCtD
Erlotinib—Neuropathy peripheral—Sorafenib—liver cancer	0.000198	0.00534	CcSEcCtD
Erlotinib—Myocardial infarction—Sorafenib—liver cancer	0.000198	0.00534	CcSEcCtD
Erlotinib—Stomatitis—Sorafenib—liver cancer	0.000197	0.00531	CcSEcCtD
Erlotinib—Folliculitis—Doxorubicin—liver cancer	0.000197	0.00529	CcSEcCtD
Erlotinib—ABL1—Idarubicin—Doxorubicin—liver cancer	0.000196	0.16	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—liver cancer	0.000196	0.16	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Doxorubicin—liver cancer	0.000196	0.16	CbGdCrCtD
Erlotinib—Haematemesis—Epirubicin—liver cancer	0.000192	0.00518	CcSEcCtD
Erlotinib—Hepatobiliary disease—Sorafenib—liver cancer	0.000191	0.00515	CcSEcCtD
Erlotinib—Epistaxis—Sorafenib—liver cancer	0.000191	0.00513	CcSEcCtD
Erlotinib—Keratitis—Doxorubicin—liver cancer	0.000191	0.00513	CcSEcCtD
Erlotinib—Nail disorder—Doxorubicin—liver cancer	0.000191	0.00513	CcSEcCtD
Erlotinib—Ileus—Epirubicin—liver cancer	0.000189	0.00508	CcSEcCtD
Erlotinib—Lung disorder—Epirubicin—liver cancer	0.000189	0.00508	CcSEcCtD
Erlotinib—FLT3—liver—liver cancer	0.000187	0.0393	CbGeAlD
Erlotinib—ABL1—embryo—liver cancer	0.000187	0.0392	CbGeAlD
Erlotinib—Blister—Epirubicin—liver cancer	0.000185	0.00499	CcSEcCtD
Erlotinib—Haemoglobin—Sorafenib—liver cancer	0.000182	0.00491	CcSEcCtD
Erlotinib—Haemorrhage—Sorafenib—liver cancer	0.000181	0.00489	CcSEcCtD
Erlotinib—Urinary tract disorder—Sorafenib—liver cancer	0.000179	0.00483	CcSEcCtD
Erlotinib—ABL2—liver—liver cancer	0.000179	0.0375	CbGeAlD
Erlotinib—Connective tissue disorder—Sorafenib—liver cancer	0.000178	0.0048	CcSEcCtD
Erlotinib—Urethral disorder—Sorafenib—liver cancer	0.000178	0.00479	CcSEcCtD
Erlotinib—Haematemesis—Doxorubicin—liver cancer	0.000178	0.00479	CcSEcCtD
Erlotinib—Lung disorder—Doxorubicin—liver cancer	0.000175	0.0047	CcSEcCtD
Erlotinib—Ileus—Doxorubicin—liver cancer	0.000175	0.0047	CcSEcCtD
Erlotinib—EGFR—liver—liver cancer	0.000175	0.0367	CbGeAlD
Erlotinib—Erythema multiforme—Sorafenib—liver cancer	0.000172	0.00462	CcSEcCtD
Erlotinib—Blister—Doxorubicin—liver cancer	0.000171	0.00462	CcSEcCtD
Erlotinib—PIP4K2C—liver—liver cancer	0.000169	0.0355	CbGeAlD
Erlotinib—Rash pustular—Epirubicin—liver cancer	0.000167	0.00451	CcSEcCtD
Erlotinib—Rigors—Epirubicin—liver cancer	0.000164	0.0044	CcSEcCtD
Erlotinib—Mediastinal disorder—Sorafenib—liver cancer	0.000164	0.0044	CcSEcCtD
Erlotinib—Arrhythmia—Sorafenib—liver cancer	0.000162	0.00437	CcSEcCtD
Erlotinib—ULK3—liver—liver cancer	0.000162	0.0339	CbGeAlD
Erlotinib—Gefitinib—CYP1A1—liver cancer	0.000161	0.101	CrCbGaD
Erlotinib—Alopecia—Sorafenib—liver cancer	0.00016	0.00432	CcSEcCtD
Erlotinib—Mental disorder—Sorafenib—liver cancer	0.000159	0.00428	CcSEcCtD
Erlotinib—Erythema—Sorafenib—liver cancer	0.000158	0.00425	CcSEcCtD
Erlotinib—Malnutrition—Sorafenib—liver cancer	0.000158	0.00425	CcSEcCtD
Erlotinib—Rash pustular—Doxorubicin—liver cancer	0.000155	0.00417	CcSEcCtD
Erlotinib—MKNK1—liver—liver cancer	0.000152	0.0319	CbGeAlD
Erlotinib—Cardiovascular disorder—Epirubicin—liver cancer	0.000152	0.00409	CcSEcCtD
Erlotinib—Rigors—Doxorubicin—liver cancer	0.000151	0.00408	CcSEcCtD
Erlotinib—Cellulitis—Epirubicin—liver cancer	0.000147	0.00395	CcSEcCtD
Erlotinib—SLK—liver—liver cancer	0.000144	0.0302	CbGeAlD
Erlotinib—Syncope—Sorafenib—liver cancer	0.000142	0.00381	CcSEcCtD
Erlotinib—Cardiovascular disorder—Doxorubicin—liver cancer	0.000141	0.00379	CcSEcCtD
Erlotinib—Bone pain—Epirubicin—liver cancer	0.000139	0.00375	CcSEcCtD
Erlotinib—Loss of consciousness—Sorafenib—liver cancer	0.000139	0.00374	CcSEcCtD
Erlotinib—Cough—Sorafenib—liver cancer	0.000138	0.00371	CcSEcCtD
Erlotinib—Inflammation—Epirubicin—liver cancer	0.000138	0.00371	CcSEcCtD
Erlotinib—Cellulitis—Doxorubicin—liver cancer	0.000136	0.00366	CcSEcCtD
Erlotinib—Musculoskeletal pain—Epirubicin—liver cancer	0.000135	0.00364	CcSEcCtD
Erlotinib—Myalgia—Sorafenib—liver cancer	0.000135	0.00362	CcSEcCtD
Erlotinib—Arthralgia—Sorafenib—liver cancer	0.000135	0.00362	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000134	0.0036	CcSEcCtD
Erlotinib—Hepatocellular injury—Epirubicin—liver cancer	0.000134	0.0036	CcSEcCtD
Erlotinib—Melaena—Epirubicin—liver cancer	0.00013	0.00351	CcSEcCtD
Erlotinib—Bone pain—Doxorubicin—liver cancer	0.000129	0.00347	CcSEcCtD
Erlotinib—Colitis—Epirubicin—liver cancer	0.000128	0.00345	CcSEcCtD
Erlotinib—Infection—Sorafenib—liver cancer	0.000128	0.00345	CcSEcCtD
Erlotinib—Skin exfoliation—Epirubicin—liver cancer	0.000128	0.00343	CcSEcCtD
Erlotinib—Inflammation—Doxorubicin—liver cancer	0.000127	0.00343	CcSEcCtD
Erlotinib—Shock—Sorafenib—liver cancer	0.000127	0.00342	CcSEcCtD
Erlotinib—Nervous system disorder—Sorafenib—liver cancer	0.000126	0.0034	CcSEcCtD
Erlotinib—Thrombocytopenia—Sorafenib—liver cancer	0.000126	0.0034	CcSEcCtD
Erlotinib—Neuropathy—Epirubicin—liver cancer	0.000125	0.00338	CcSEcCtD
Erlotinib—Skin disorder—Sorafenib—liver cancer	0.000125	0.00337	CcSEcCtD
Erlotinib—STK10—liver—liver cancer	0.000125	0.0263	CbGeAlD
Erlotinib—Musculoskeletal pain—Doxorubicin—liver cancer	0.000125	0.00337	CcSEcCtD
Erlotinib—Hepatocellular injury—Doxorubicin—liver cancer	0.000124	0.00333	CcSEcCtD
Erlotinib—Dry eye—Epirubicin—liver cancer	0.000123	0.00332	CcSEcCtD
Erlotinib—Anorexia—Sorafenib—liver cancer	0.000123	0.00331	CcSEcCtD
Erlotinib—Melaena—Doxorubicin—liver cancer	0.000121	0.00325	CcSEcCtD
Erlotinib—Colitis—Doxorubicin—liver cancer	0.000119	0.00319	CcSEcCtD
Erlotinib—UGT1A1—liver—liver cancer	0.000118	0.0248	CbGeAlD
Erlotinib—Skin exfoliation—Doxorubicin—liver cancer	0.000118	0.00318	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000117	0.00316	CcSEcCtD
Erlotinib—Neuropathy—Doxorubicin—liver cancer	0.000116	0.00312	CcSEcCtD
Erlotinib—Sepsis—Epirubicin—liver cancer	0.000116	0.00312	CcSEcCtD
Erlotinib—Dyspnoea—Sorafenib—liver cancer	0.000115	0.0031	CcSEcCtD
Erlotinib—Dry eye—Doxorubicin—liver cancer	0.000114	0.00307	CcSEcCtD
Erlotinib—Dyspepsia—Sorafenib—liver cancer	0.000114	0.00306	CcSEcCtD
Erlotinib—Decreased appetite—Sorafenib—liver cancer	0.000112	0.00302	CcSEcCtD
Erlotinib—MAP2K5—liver—liver cancer	0.000112	0.0235	CbGeAlD
Erlotinib—Gastrointestinal disorder—Sorafenib—liver cancer	0.000111	0.003	CcSEcCtD
Erlotinib—Fatigue—Sorafenib—liver cancer	0.000111	0.00299	CcSEcCtD
Erlotinib—Pain—Sorafenib—liver cancer	0.00011	0.00297	CcSEcCtD
Erlotinib—Constipation—Sorafenib—liver cancer	0.00011	0.00297	CcSEcCtD
Erlotinib—Hepatic failure—Epirubicin—liver cancer	0.000108	0.0029	CcSEcCtD
Erlotinib—Sepsis—Doxorubicin—liver cancer	0.000107	0.00289	CcSEcCtD
Erlotinib—Gastrointestinal pain—Sorafenib—liver cancer	0.000105	0.00284	CcSEcCtD
Erlotinib—Renal failure acute—Epirubicin—liver cancer	0.000105	0.00283	CcSEcCtD
Erlotinib—Abdominal pain—Sorafenib—liver cancer	0.000102	0.00274	CcSEcCtD
Erlotinib—Body temperature increased—Sorafenib—liver cancer	0.000102	0.00274	CcSEcCtD
Erlotinib—Renal impairment—Epirubicin—liver cancer	0.000102	0.00274	CcSEcCtD
Erlotinib—Dermatitis bullous—Epirubicin—liver cancer	0.000101	0.00273	CcSEcCtD
Erlotinib—Hepatic failure—Doxorubicin—liver cancer	9.98e-05	0.00269	CcSEcCtD
Erlotinib—Cerebrovascular accident—Epirubicin—liver cancer	9.89e-05	0.00266	CcSEcCtD
Erlotinib—Renal failure acute—Doxorubicin—liver cancer	9.72e-05	0.00262	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Epirubicin—liver cancer	9.7e-05	0.00261	CcSEcCtD
Erlotinib—Vandetanib—ALB—liver cancer	9.43e-05	0.0591	CrCbGaD
Erlotinib—Renal impairment—Doxorubicin—liver cancer	9.43e-05	0.00254	CcSEcCtD
Erlotinib—Dermatitis bullous—Doxorubicin—liver cancer	9.39e-05	0.00253	CcSEcCtD
Erlotinib—Asthenia—Sorafenib—liver cancer	9.25e-05	0.00249	CcSEcCtD
Erlotinib—Cerebrovascular accident—Doxorubicin—liver cancer	9.15e-05	0.00246	CcSEcCtD
Erlotinib—Pruritus—Sorafenib—liver cancer	9.12e-05	0.00246	CcSEcCtD
Erlotinib—ORM1—liver—liver cancer	9.08e-05	0.0191	CbGeAlD
Erlotinib—Dehydration—Epirubicin—liver cancer	9.02e-05	0.00243	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	8.97e-05	0.00242	CcSEcCtD
Erlotinib—Gefitinib—ALB—liver cancer	8.96e-05	0.0561	CrCbGaD
Erlotinib—Dry skin—Epirubicin—liver cancer	8.89e-05	0.00239	CcSEcCtD
Erlotinib—Hypokalaemia—Epirubicin—liver cancer	8.82e-05	0.00238	CcSEcCtD
Erlotinib—Diarrhoea—Sorafenib—liver cancer	8.82e-05	0.00238	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Epirubicin—liver cancer	8.73e-05	0.00235	CcSEcCtD
Erlotinib—SLCO2B1—liver—liver cancer	8.7e-05	0.0183	CbGeAlD
Erlotinib—ABL1—liver—liver cancer	8.63e-05	0.0181	CbGeAlD
Erlotinib—Gastritis—Epirubicin—liver cancer	8.58e-05	0.00231	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Epirubicin—liver cancer	8.55e-05	0.0023	CcSEcCtD
Erlotinib—Dizziness—Sorafenib—liver cancer	8.53e-05	0.0023	CcSEcCtD
Erlotinib—Dysphagia—Epirubicin—liver cancer	8.38e-05	0.00226	CcSEcCtD
Erlotinib—Dehydration—Doxorubicin—liver cancer	8.34e-05	0.00225	CcSEcCtD
Erlotinib—Dry skin—Doxorubicin—liver cancer	8.22e-05	0.00221	CcSEcCtD
Erlotinib—Pancreatitis—Epirubicin—liver cancer	8.22e-05	0.00221	CcSEcCtD
Erlotinib—Vomiting—Sorafenib—liver cancer	8.2e-05	0.00221	CcSEcCtD
Erlotinib—Hypokalaemia—Doxorubicin—liver cancer	8.16e-05	0.0022	CcSEcCtD
Erlotinib—Rash—Sorafenib—liver cancer	8.13e-05	0.00219	CcSEcCtD
Erlotinib—Dermatitis—Sorafenib—liver cancer	8.12e-05	0.00219	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Doxorubicin—liver cancer	8.08e-05	0.00218	CcSEcCtD
Erlotinib—Headache—Sorafenib—liver cancer	8.08e-05	0.00217	CcSEcCtD
Erlotinib—ALB—liver—liver cancer	7.96e-05	0.0167	CbGeAlD
Erlotinib—Gastritis—Doxorubicin—liver cancer	7.94e-05	0.00214	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Doxorubicin—liver cancer	7.91e-05	0.00213	CcSEcCtD
Erlotinib—Neutropenia—Epirubicin—liver cancer	7.84e-05	0.00211	CcSEcCtD
Erlotinib—Dysphagia—Doxorubicin—liver cancer	7.75e-05	0.00209	CcSEcCtD
Erlotinib—Nausea—Sorafenib—liver cancer	7.66e-05	0.00206	CcSEcCtD
Erlotinib—Pancreatitis—Doxorubicin—liver cancer	7.6e-05	0.00205	CcSEcCtD
Erlotinib—Weight decreased—Epirubicin—liver cancer	7.58e-05	0.00204	CcSEcCtD
Erlotinib—Pneumonia—Epirubicin—liver cancer	7.52e-05	0.00202	CcSEcCtD
Erlotinib—Infestation—Epirubicin—liver cancer	7.47e-05	0.00201	CcSEcCtD
Erlotinib—Infestation NOS—Epirubicin—liver cancer	7.47e-05	0.00201	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Epirubicin—liver cancer	7.41e-05	0.00199	CcSEcCtD
Erlotinib—Renal failure—Epirubicin—liver cancer	7.34e-05	0.00198	CcSEcCtD
Erlotinib—Neuropathy peripheral—Epirubicin—liver cancer	7.32e-05	0.00197	CcSEcCtD
Erlotinib—CYP1B1—liver—liver cancer	7.31e-05	0.0153	CbGeAlD
Erlotinib—Stomatitis—Epirubicin—liver cancer	7.28e-05	0.00196	CcSEcCtD
Erlotinib—Conjunctivitis—Epirubicin—liver cancer	7.26e-05	0.00196	CcSEcCtD
Erlotinib—Neutropenia—Doxorubicin—liver cancer	7.25e-05	0.00195	CcSEcCtD
Erlotinib—Hepatobiliary disease—Epirubicin—liver cancer	7.07e-05	0.0019	CcSEcCtD
Erlotinib—Epistaxis—Epirubicin—liver cancer	7.05e-05	0.0019	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—liver cancer	7.01e-05	0.00189	CcSEcCtD
Erlotinib—Pneumonia—Doxorubicin—liver cancer	6.95e-05	0.00187	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—liver cancer	6.91e-05	0.00186	CcSEcCtD
Erlotinib—Infestation—Doxorubicin—liver cancer	6.91e-05	0.00186	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—liver cancer	6.85e-05	0.00185	CcSEcCtD
Erlotinib—Renal failure—Doxorubicin—liver cancer	6.8e-05	0.00183	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—liver cancer	6.78e-05	0.00182	CcSEcCtD
Erlotinib—Haemoglobin—Epirubicin—liver cancer	6.74e-05	0.00182	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—liver cancer	6.74e-05	0.00181	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—liver cancer	6.72e-05	0.00181	CcSEcCtD
Erlotinib—Hepatitis—Epirubicin—liver cancer	6.71e-05	0.00181	CcSEcCtD
Erlotinib—Haemorrhage—Epirubicin—liver cancer	6.71e-05	0.00181	CcSEcCtD
Erlotinib—Urinary tract disorder—Epirubicin—liver cancer	6.62e-05	0.00178	CcSEcCtD
Erlotinib—Connective tissue disorder—Epirubicin—liver cancer	6.59e-05	0.00177	CcSEcCtD
Erlotinib—Urethral disorder—Epirubicin—liver cancer	6.58e-05	0.00177	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—liver cancer	6.54e-05	0.00176	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—liver cancer	6.52e-05	0.00176	CcSEcCtD
Erlotinib—Erythema multiforme—Epirubicin—liver cancer	6.34e-05	0.00171	CcSEcCtD
Erlotinib—Eye disorder—Epirubicin—liver cancer	6.27e-05	0.00169	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—liver cancer	6.24e-05	0.00168	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—liver cancer	6.21e-05	0.00167	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—liver cancer	6.21e-05	0.00167	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—liver cancer	6.13e-05	0.00165	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—liver cancer	6.1e-05	0.00164	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—liver cancer	6.08e-05	0.00164	CcSEcCtD
Erlotinib—Mediastinal disorder—Epirubicin—liver cancer	6.05e-05	0.00163	CcSEcCtD
Erlotinib—Chills—Epirubicin—liver cancer	6.02e-05	0.00162	CcSEcCtD
Erlotinib—Arrhythmia—Epirubicin—liver cancer	5.99e-05	0.00161	CcSEcCtD
Erlotinib—Alopecia—Epirubicin—liver cancer	5.93e-05	0.0016	CcSEcCtD
Erlotinib—Mental disorder—Epirubicin—liver cancer	5.88e-05	0.00158	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—liver cancer	5.87e-05	0.00158	CcSEcCtD
Erlotinib—Erythema—Epirubicin—liver cancer	5.84e-05	0.00157	CcSEcCtD
Erlotinib—Malnutrition—Epirubicin—liver cancer	5.84e-05	0.00157	CcSEcCtD
Erlotinib—ABCB1—embryo—liver cancer	5.8e-05	0.0122	CbGeAlD
Erlotinib—Eye disorder—Doxorubicin—liver cancer	5.8e-05	0.00156	CcSEcCtD
Erlotinib—Flatulence—Epirubicin—liver cancer	5.75e-05	0.00155	CcSEcCtD
Erlotinib—Back pain—Epirubicin—liver cancer	5.65e-05	0.00152	CcSEcCtD
Erlotinib—CYP2C8—liver—liver cancer	5.6e-05	0.0117	CbGeAlD
Erlotinib—Mediastinal disorder—Doxorubicin—liver cancer	5.59e-05	0.00151	CcSEcCtD
Erlotinib—Chills—Doxorubicin—liver cancer	5.57e-05	0.0015	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—liver cancer	5.54e-05	0.00149	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—liver cancer	5.48e-05	0.00148	CcSEcCtD
Erlotinib—ABCG2—liver—liver cancer	5.44e-05	0.0114	CbGeAlD
Erlotinib—Mental disorder—Doxorubicin—liver cancer	5.44e-05	0.00146	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—liver cancer	5.4e-05	0.00145	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—liver cancer	5.4e-05	0.00145	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—liver cancer	5.32e-05	0.00143	CcSEcCtD
Erlotinib—Syncope—Epirubicin—liver cancer	5.24e-05	0.00141	CcSEcCtD
Erlotinib—CYP1A2—liver—liver cancer	5.24e-05	0.011	CbGeAlD
Erlotinib—Back pain—Doxorubicin—liver cancer	5.23e-05	0.00141	CcSEcCtD
Erlotinib—CYP1A1—liver—liver cancer	5.16e-05	0.0108	CbGeAlD
Erlotinib—Loss of consciousness—Epirubicin—liver cancer	5.13e-05	0.00138	CcSEcCtD
Erlotinib—Cough—Epirubicin—liver cancer	5.1e-05	0.00137	CcSEcCtD
Erlotinib—CYP3A5—liver—liver cancer	5.05e-05	0.0106	CbGeAlD
Erlotinib—Chest pain—Epirubicin—liver cancer	4.97e-05	0.00134	CcSEcCtD
Erlotinib—Arthralgia—Epirubicin—liver cancer	4.97e-05	0.00134	CcSEcCtD
Erlotinib—Myalgia—Epirubicin—liver cancer	4.97e-05	0.00134	CcSEcCtD
Erlotinib—Anxiety—Epirubicin—liver cancer	4.95e-05	0.00133	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	4.94e-05	0.00133	CcSEcCtD
Erlotinib—Syncope—Doxorubicin—liver cancer	4.84e-05	0.0013	CcSEcCtD
Erlotinib—Oedema—Epirubicin—liver cancer	4.77e-05	0.00128	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—liver cancer	4.75e-05	0.00128	CcSEcCtD
Erlotinib—Infection—Epirubicin—liver cancer	4.73e-05	0.00127	CcSEcCtD
Erlotinib—Cough—Doxorubicin—liver cancer	4.71e-05	0.00127	CcSEcCtD
Erlotinib—Shock—Epirubicin—liver cancer	4.69e-05	0.00126	CcSEcCtD
Erlotinib—Nervous system disorder—Epirubicin—liver cancer	4.67e-05	0.00126	CcSEcCtD
Erlotinib—Thrombocytopenia—Epirubicin—liver cancer	4.67e-05	0.00126	CcSEcCtD
Erlotinib—Skin disorder—Epirubicin—liver cancer	4.63e-05	0.00125	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—liver cancer	4.6e-05	0.00124	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—liver cancer	4.6e-05	0.00124	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—liver cancer	4.6e-05	0.00124	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—liver cancer	4.58e-05	0.00123	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	4.57e-05	0.00123	CcSEcCtD
Erlotinib—Anorexia—Epirubicin—liver cancer	4.54e-05	0.00122	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—liver cancer	4.41e-05	0.00119	CcSEcCtD
Erlotinib—Infection—Doxorubicin—liver cancer	4.38e-05	0.00118	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Epirubicin—liver cancer	4.34e-05	0.00117	CcSEcCtD
Erlotinib—Shock—Doxorubicin—liver cancer	4.34e-05	0.00117	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—liver cancer	4.32e-05	0.00116	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—liver cancer	4.32e-05	0.00116	CcSEcCtD
Erlotinib—Insomnia—Epirubicin—liver cancer	4.31e-05	0.00116	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—liver cancer	4.28e-05	0.00115	CcSEcCtD
Erlotinib—Dyspnoea—Epirubicin—liver cancer	4.25e-05	0.00114	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—liver cancer	4.2e-05	0.00113	CcSEcCtD
Erlotinib—Dyspepsia—Epirubicin—liver cancer	4.19e-05	0.00113	CcSEcCtD
Erlotinib—Decreased appetite—Epirubicin—liver cancer	4.14e-05	0.00112	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Epirubicin—liver cancer	4.11e-05	0.00111	CcSEcCtD
Erlotinib—Fatigue—Epirubicin—liver cancer	4.11e-05	0.00111	CcSEcCtD
Erlotinib—Constipation—Epirubicin—liver cancer	4.08e-05	0.0011	CcSEcCtD
Erlotinib—Pain—Epirubicin—liver cancer	4.08e-05	0.0011	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—liver cancer	4.02e-05	0.00108	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—liver cancer	3.99e-05	0.00107	CcSEcCtD
Erlotinib—Dyspnoea—Doxorubicin—liver cancer	3.93e-05	0.00106	CcSEcCtD
Erlotinib—Gastrointestinal pain—Epirubicin—liver cancer	3.9e-05	0.00105	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—liver cancer	3.88e-05	0.00105	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—liver cancer	3.83e-05	0.00103	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—liver cancer	3.81e-05	0.00102	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—liver cancer	3.8e-05	0.00102	CcSEcCtD
Erlotinib—CYP3A4—liver—liver cancer	3.79e-05	0.00796	CbGeAlD
Erlotinib—Pain—Doxorubicin—liver cancer	3.77e-05	0.00102	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—liver cancer	3.77e-05	0.00102	CcSEcCtD
Erlotinib—Abdominal pain—Epirubicin—liver cancer	3.77e-05	0.00101	CcSEcCtD
Erlotinib—Body temperature increased—Epirubicin—liver cancer	3.77e-05	0.00101	CcSEcCtD
Erlotinib—CYP2D6—liver—liver cancer	3.73e-05	0.00783	CbGeAlD
Erlotinib—Gastrointestinal pain—Doxorubicin—liver cancer	3.61e-05	0.000971	CcSEcCtD
Erlotinib—Body temperature increased—Doxorubicin—liver cancer	3.49e-05	0.000938	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—liver cancer	3.49e-05	0.000938	CcSEcCtD
Erlotinib—Asthenia—Epirubicin—liver cancer	3.42e-05	0.000921	CcSEcCtD
Erlotinib—Pruritus—Epirubicin—liver cancer	3.37e-05	0.000908	CcSEcCtD
Erlotinib—Diarrhoea—Epirubicin—liver cancer	3.26e-05	0.000878	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—liver cancer	3.16e-05	0.000852	CcSEcCtD
Erlotinib—Dizziness—Epirubicin—liver cancer	3.15e-05	0.000848	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—liver cancer	3.12e-05	0.00084	CcSEcCtD
Erlotinib—Vomiting—Epirubicin—liver cancer	3.03e-05	0.000816	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—liver cancer	3.02e-05	0.000812	CcSEcCtD
Erlotinib—Rash—Epirubicin—liver cancer	3e-05	0.000809	CcSEcCtD
Erlotinib—Dermatitis—Epirubicin—liver cancer	3e-05	0.000808	CcSEcCtD
Erlotinib—Headache—Epirubicin—liver cancer	2.99e-05	0.000804	CcSEcCtD
Erlotinib—Dizziness—Doxorubicin—liver cancer	2.92e-05	0.000785	CcSEcCtD
Erlotinib—Nausea—Epirubicin—liver cancer	2.83e-05	0.000762	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—liver cancer	2.8e-05	0.000755	CcSEcCtD
Erlotinib—Rash—Doxorubicin—liver cancer	2.78e-05	0.000749	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—liver cancer	2.78e-05	0.000748	CcSEcCtD
Erlotinib—Headache—Doxorubicin—liver cancer	2.76e-05	0.000744	CcSEcCtD
Erlotinib—ABCB1—liver—liver cancer	2.68e-05	0.00563	CbGeAlD
Erlotinib—Nausea—Doxorubicin—liver cancer	2.62e-05	0.000705	CcSEcCtD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—liver cancer	1.37e-06	2.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDKN1B—liver cancer	1.37e-06	2.49e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTP1—liver cancer	1.36e-06	2.48e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PSMA4—liver cancer	1.36e-06	2.47e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PSMD10—liver cancer	1.36e-06	2.47e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—STAT3—liver cancer	1.36e-06	2.47e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—liver cancer	1.36e-06	2.47e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IL6—liver cancer	1.35e-06	2.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MTOR—liver cancer	1.35e-06	2.45e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CB—liver cancer	1.35e-06	2.45e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—HMOX1—liver cancer	1.34e-06	2.44e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTA4—liver cancer	1.34e-06	2.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL2—liver cancer	1.34e-06	2.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KDR—liver cancer	1.34e-06	2.43e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.33e-06	2.42e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CD—liver cancer	1.33e-06	2.41e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK14—liver cancer	1.33e-06	2.41e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PPARG—liver cancer	1.33e-06	2.41e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTM1—liver cancer	1.33e-06	2.41e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GOT2—liver cancer	1.32e-06	2.41e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP2E1—liver cancer	1.32e-06	2.4e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—STAT3—liver cancer	1.32e-06	2.4e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PIK3CA—liver cancer	1.31e-06	2.39e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ALB—liver cancer	1.31e-06	2.38e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTA2—liver cancer	1.31e-06	2.38e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—JUN—liver cancer	1.3e-06	2.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ESR1—liver cancer	1.3e-06	2.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CTNNB1—liver cancer	1.29e-06	2.35e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HPGDS—liver cancer	1.29e-06	2.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—F2—liver cancer	1.29e-06	2.34e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.29e-06	2.34e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—liver cancer	1.27e-06	2.31e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDKN1B—liver cancer	1.26e-06	2.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDKN1A—liver cancer	1.26e-06	2.3e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTA1—liver cancer	1.26e-06	2.29e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—liver cancer	1.26e-06	2.29e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TGFB1—liver cancer	1.26e-06	2.29e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP1A1—liver cancer	1.26e-06	2.28e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTM1—liver cancer	1.25e-06	2.28e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—liver cancer	1.25e-06	2.27e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTP1—liver cancer	1.25e-06	2.27e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NAT2—liver cancer	1.25e-06	2.27e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—AKT1—liver cancer	1.25e-06	2.27e-05	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	1.25e-06	2.26e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP2E1—liver cancer	1.24e-06	2.26e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTP1—liver cancer	1.24e-06	2.26e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CB—liver cancer	1.24e-06	2.26e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYCS—liver cancer	1.24e-06	2.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK8—liver cancer	1.23e-06	2.24e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—HMOX1—liver cancer	1.23e-06	2.24e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APC—liver cancer	1.23e-06	2.24e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CG—liver cancer	1.23e-06	2.24e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—HMOX1—liver cancer	1.23e-06	2.23e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—liver cancer	1.22e-06	2.21e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GGT1—liver cancer	1.21e-06	2.2e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GOT1—liver cancer	1.21e-06	2.2e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CD—liver cancer	1.21e-06	2.2e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—liver cancer	1.2e-06	2.18e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALDOB—liver cancer	1.2e-06	2.18e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CTNNB1—liver cancer	1.19e-06	2.17e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ALB—liver cancer	1.19e-06	2.17e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTHFR—liver cancer	1.17e-06	2.13e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.17e-06	2.13e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDKN1A—liver cancer	1.17e-06	2.12e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—liver cancer	1.17e-06	2.12e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYCS—liver cancer	1.16e-06	2.12e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—liver cancer	1.16e-06	2.12e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CB—liver cancer	1.16e-06	2.1e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—BRAF—liver cancer	1.16e-06	2.1e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.16e-06	2.1e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PSMA4—liver cancer	1.15e-06	2.09e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PSMD10—liver cancer	1.15e-06	2.09e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARA—liver cancer	1.15e-06	2.09e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTM1—liver cancer	1.15e-06	2.09e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TGFB1—liver cancer	1.15e-06	2.09e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GOT1—liver cancer	1.14e-06	2.08e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GGT1—liver cancer	1.14e-06	2.08e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTM1—liver cancer	1.14e-06	2.08e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CRABP1—liver cancer	1.14e-06	2.08e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—liver cancer	1.13e-06	2.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STAT3—liver cancer	1.13e-06	2.05e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GOT2—liver cancer	1.12e-06	2.04e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTHFR—liver cancer	1.11e-06	2.01e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTP1—liver cancer	1.09e-06	1.98e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP1A1—liver cancer	1.09e-06	1.98e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARA—liver cancer	1.09e-06	1.97e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP1A1—liver cancer	1.08e-06	1.97e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CD—liver cancer	1.08e-06	1.97e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—HMOX1—liver cancer	1.07e-06	1.95e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—liver cancer	1.07e-06	1.95e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—liver cancer	1.07e-06	1.95e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SERPINE1—liver cancer	1.07e-06	1.95e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—liver cancer	1.06e-06	1.93e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—liver cancer	1.06e-06	1.93e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP2E1—liver cancer	1.05e-06	1.92e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CB—liver cancer	1.05e-06	1.91e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—liver cancer	1.04e-06	1.89e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—liver cancer	1.04e-06	1.89e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—liver cancer	1.04e-06	1.88e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTP1—liver cancer	1.03e-06	1.87e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.02e-06	1.85e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—liver cancer	1.02e-06	1.85e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HMOX1—liver cancer	1.01e-06	1.84e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—liver cancer	1.01e-06	1.83e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTM1—liver cancer	1e-06	1.82e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HPGDS—liver cancer	9.98e-07	1.81e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARA—liver cancer	9.96e-07	1.81e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—liver cancer	9.92e-07	1.8e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARA—liver cancer	9.9e-07	1.8e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYCS—liver cancer	9.86e-07	1.79e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CG—liver cancer	9.85e-07	1.79e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—liver cancer	9.77e-07	1.78e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	9.76e-07	1.77e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—liver cancer	9.74e-07	1.77e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—liver cancer	9.68e-07	1.76e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GOT1—liver cancer	9.68e-07	1.76e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GGT1—liver cancer	9.68e-07	1.76e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—liver cancer	9.67e-07	1.76e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RAF1—liver cancer	9.66e-07	1.76e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFB1—liver cancer	9.65e-07	1.75e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—liver cancer	9.63e-07	1.75e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARG—liver cancer	9.51e-07	1.73e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—liver cancer	9.49e-07	1.72e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP1A1—liver cancer	9.49e-07	1.72e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—liver cancer	9.45e-07	1.72e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CB—liver cancer	9.43e-07	1.71e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MTOR—liver cancer	9.43e-07	1.71e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTM1—liver cancer	9.43e-07	1.71e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CG—liver cancer	9.3e-07	1.69e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—liver cancer	9.22e-07	1.67e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—liver cancer	9.04e-07	1.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—liver cancer	9.01e-07	1.64e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARG—liver cancer	8.98e-07	1.63e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	8.95e-07	1.63e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP1A1—liver cancer	8.94e-07	1.62e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—liver cancer	8.94e-07	1.62e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	8.9e-07	1.62e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PSMD10—liver cancer	8.9e-07	1.62e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PSMA4—liver cancer	8.9e-07	1.62e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—liver cancer	8.89e-07	1.62e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1B—liver cancer	8.85e-07	1.61e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—liver cancer	8.85e-07	1.61e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—liver cancer	8.75e-07	1.59e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTP1—liver cancer	8.69e-07	1.58e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARA—liver cancer	8.68e-07	1.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—liver cancer	8.68e-07	1.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—liver cancer	8.66e-07	1.57e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CD—liver cancer	8.66e-07	1.57e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GOT2—liver cancer	8.65e-07	1.57e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—liver cancer	8.62e-07	1.57e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HMOX1—liver cancer	8.57e-07	1.56e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ALB—liver cancer	8.55e-07	1.55e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CG—liver cancer	8.53e-07	1.55e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—liver cancer	8.5e-07	1.55e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CG—liver cancer	8.48e-07	1.54e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—liver cancer	8.45e-07	1.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—JUN—liver cancer	8.43e-07	1.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CTNNB1—liver cancer	8.36e-07	1.52e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—liver cancer	8.34e-07	1.51e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARG—liver cancer	8.23e-07	1.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—liver cancer	8.23e-07	1.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—liver cancer	8.21e-07	1.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—liver cancer	8.2e-07	1.49e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARG—liver cancer	8.19e-07	1.49e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CD—liver cancer	8.18e-07	1.49e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARA—liver cancer	8.18e-07	1.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1A—liver cancer	8.17e-07	1.48e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2E1—liver cancer	8.14e-07	1.48e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ALB—liver cancer	8.07e-07	1.47e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTM1—liver cancer	7.99e-07	1.45e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—liver cancer	7.98e-07	1.45e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK8—liver cancer	7.97e-07	1.45e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—liver cancer	7.95e-07	1.45e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—liver cancer	7.88e-07	1.43e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYCS—liver cancer	7.61e-07	1.38e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—liver cancer	7.6e-07	1.38e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP1A1—liver cancer	7.57e-07	1.38e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—liver cancer	7.57e-07	1.38e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CB—liver cancer	7.55e-07	1.37e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CD—liver cancer	7.5e-07	1.36e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GOT1—liver cancer	7.47e-07	1.36e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GGT1—liver cancer	7.47e-07	1.36e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CD—liver cancer	7.46e-07	1.35e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CG—liver cancer	7.43e-07	1.35e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ALB—liver cancer	7.4e-07	1.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—liver cancer	7.36e-07	1.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—liver cancer	7.29e-07	1.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—liver cancer	7.27e-07	1.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—liver cancer	7.27e-07	1.32e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARG—liver cancer	7.17e-07	1.3e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CB—liver cancer	7.13e-07	1.3e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—liver cancer	7.06e-07	1.28e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—liver cancer	7.06e-07	1.28e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CG—liver cancer	7e-07	1.27e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARA—liver cancer	6.93e-07	1.26e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—liver cancer	6.77e-07	1.23e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARG—liver cancer	6.76e-07	1.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFB1—liver cancer	6.76e-07	1.23e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTP1—liver cancer	6.71e-07	1.22e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—liver cancer	6.71e-07	1.22e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HMOX1—liver cancer	6.62e-07	1.2e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CB—liver cancer	6.54e-07	1.19e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CD—liver cancer	6.53e-07	1.19e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CB—liver cancer	6.5e-07	1.18e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ALB—liver cancer	6.45e-07	1.17e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—liver cancer	6.42e-07	1.17e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—liver cancer	6.26e-07	1.14e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.22e-07	1.13e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—liver cancer	6.18e-07	1.12e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTM1—liver cancer	6.17e-07	1.12e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CD—liver cancer	6.16e-07	1.12e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ALB—liver cancer	6.08e-07	1.1e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CG—liver cancer	5.93e-07	1.08e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP1A1—liver cancer	5.85e-07	1.06e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—liver cancer	5.77e-07	1.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—liver cancer	5.75e-07	1.05e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARG—liver cancer	5.73e-07	1.04e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CB—liver cancer	5.69e-07	1.03e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—liver cancer	5.56e-07	1.01e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—liver cancer	5.45e-07	9.9e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CB—liver cancer	5.37e-07	9.75e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARA—liver cancer	5.35e-07	9.72e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—liver cancer	5.32e-07	9.67e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—liver cancer	5.25e-07	9.53e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CD—liver cancer	5.22e-07	9.48e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALB—liver cancer	5.15e-07	9.36e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—liver cancer	5.09e-07	9.25e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—liver cancer	4.7e-07	8.54e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—liver cancer	4.6e-07	8.36e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CG—liver cancer	4.58e-07	8.32e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CB—liver cancer	4.55e-07	8.26e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARG—liver cancer	4.42e-07	8.03e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—liver cancer	4.35e-07	7.9e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CD—liver cancer	4.03e-07	7.31e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—liver cancer	3.98e-07	7.24e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALB—liver cancer	3.97e-07	7.22e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—liver cancer	3.96e-07	7.2e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—liver cancer	3.76e-07	6.83e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—liver cancer	3.55e-07	6.45e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CB—liver cancer	3.51e-07	6.38e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—liver cancer	3.47e-07	6.31e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—liver cancer	3.27e-07	5.94e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—liver cancer	3.26e-07	5.92e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—liver cancer	3.24e-07	5.88e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—liver cancer	2.84e-07	5.15e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—liver cancer	2.77e-07	5.04e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—liver cancer	2.67e-07	4.86e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—liver cancer	2.26e-07	4.11e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—liver cancer	2.14e-07	3.89e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—liver cancer	1.75e-07	3.18e-06	CbGpPWpGaD
